0001144204-11-067272 Sample Contracts

FORM OF SERIES A WARRANT] RADIENT PHARMACEUTICALS CORPORATION Warrant To Purchase Common Stock
Warrant Agreement • November 29th, 2011 • RADIENT PHARMACEUTICALS Corp • Pharmaceutical preparations • New York

Radient Pharmaceuticals Corporation, a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [_____________], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after the Issuance Date, but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), ______________ (_____________) fully paid, nonassessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this “Warrant”), shall have the meanings set forth in Section 17. This Warrant

AutoNDA by SimpleDocs
Agreement
Settlement Agreement • November 29th, 2011 • RADIENT PHARMACEUTICALS Corp • Pharmaceutical preparations • New York

THIS AGREEMENT (“Agreement”) is made and entered into this 28th day of November, 2011 between Whalehaven Capital Fund, Ltd. (“Whalehaven”) and Radient Pharmaceuticals Corporation (“RPC” or the “Company”). Whalehaven is hereinafter sometimes referred to as “Holder”, Whalehaven and RPC are hereinafter sometimes individually referred to as a “Party” and collectively as the “Parties.”

FORM OF SERIES B WARRANT] RADIENT PHARMACEUTICALS CORPORATION Warrant To Purchase Series C Convertible Preferred Stock
Warrant Agreement • November 29th, 2011 • RADIENT PHARMACEUTICALS Corp • Pharmaceutical preparations • New York

Radient Pharmaceuticals Corporation, a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [_____________], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after the Issuance Date, but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), ______________ (_____________) fully paid, nonassessable shares of Series C Preferred Stock (as defined below), subject to adjustment as provided herein (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Series C Convertible Preferred Stock (including any Warrants to Purchase Series C Convertible Preferred Stock issued in exchange, transfer or replacement hereof, this “Warrant”), s

EXCHANGE AGREEMENT
Exchange Agreement • November 29th, 2011 • RADIENT PHARMACEUTICALS Corp • Pharmaceutical preparations • New York

This EXCHANGE AGREEMENT (the “Agreement”), dated as of November 28, 2011 (the “Execution Date”), is made and entered into by and between Radient Pharmaceuticals Corporation, a Delaware corporation (the “Company”) and [_________________] (the “Holder”).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!